TMX1 and breast carcinoma: Here, we identified a potential biomarker of TMX resistance, SULT1A1, which is upregulated after TMX treatment in metastatic breast cancers in relapsed patients, in treated breast cancer samples ex vivo and in breast cancer cell lines in vitro.